AVEO Pharmaceuticals, Inc.'s Tivozanib in Combination with FOLFOX6 Demonstrates Anti-tumor Activity and Safety in Advanced GI Cancers; Results Presented at European Organization for Research and Treatment of Cancer-National Cancer Institute-American Assoc

CAMBRIDGE, Mass. & BERLIN--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical trial evaluating the company’s lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, in patients with advanced gastrointestinal (GI) cancers. Results show partial responses in more than a third (35 percent) of patients evaluated (n=17) and disease control in 82 percent of patients; and, the combination was considered safe in the Phase 1b clinical trial at the full recommended tivozanib dose (1.5 mg/day) and standard FOLFOX6 dose. These data were presented today during the 22nd Annual Symposium of the European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research (EORTC-NCI-AACR) in Berlin, Germany.